# CATALYST PHARMACEUTICALS, INC. (CPRX) — merger [completed]
Source: SEC API (secapi.ai) · situation sit_732aafec86c0e2f61024 · retrieved 2026-08-12T21:20:50.154Z

## Overview
Catalyst Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes pharmaceutical products.

On July 8, 2026, Catalyst Pharmaceuticals, Inc. held a special stockholder meeting to vote on its proposed merger with Angelini Pharma S.p.A., an Italian pharmaceutical company. The merger was approved by shareholders, with 97,340,180 votes in favor, 1,143,815 votes against, and 242,616 abstentions out of 98,726,611 shares present (80.6% of outstanding shares). Under the Agreement and Plan of Merger dated May 6, 2026, Angelini Cielo Inc., a wholly-owned subsidiary of Angelini Pharma, will merge with and into Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The merger approval satisfies one of the closing conditions under the Merger Agreement.

## Terms
- Counterparty: Angelini Pharma S.p.A. · Stake: 100%

## Key dates
- Record 2026-06-03 · Vote 2026-07-08 · Completed 2026-07-15

## Timeline
- 2026-07-08 · 8-K (0001193125-26-298739): 8-K - CATALYST PHARMACEUTICALS, INC. — *Catalyst Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes pharmaceutical products.* On July 8, 2026, Catalyst Pharmaceuticals, Inc. held a special stockholder meeting to vote on its proposed merger with Angelini Pharma S.p.A., an Italian pharmaceutical company. The merger was approved by shareholders, with 97,340,180 votes in favor, 1,143,815 votes against, and 242,616 abstentions out of 98,726,611 shares present (80.6% of outstanding shares). Under the Agreement and Plan of Merger dated May 6, 2026, Angelini Cielo Inc., a wholly-owned subsidiary of Angelini Pharma, will merge with and into Catalyst, with Catalyst surviving as a wholly-owned subsidiary of Angelini Pharma. The merger approval satisfies one of the closing conditions under the Merger Agreement.
  https://www.sec.gov/Archives/edgar/data/1369568/0001193125-26-298739.txt
- 2026-07-15 · 8-K (0001193125-26-304984): 8-K 8-K
  https://www.sec.gov/Archives/edgar/data/1369568/000119312526304984/d159184d8k.htm

## Citations
- 0001193125-26-298739 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526298739
- 0001193125-26-304984 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000119312526304984